Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions

Details for Australian Patent Application No. 2006259898 (hide)

Owner AstraZeneca AB

Inventors Dahlstrom, Mikael; Starke, Ingemar; Alenfalk, Susanne; Karlsson, Staffan; Hunegnaw, Fana

Agent Davies Collison Cave

Pub. Number AU-B-2006259898

PCT Pub. Number WO2006/137797

Priority 0501464-2 22.06.05 SE

Filing date 21 June 2006

Wipo publication date 28 December 2006

Acceptance publication date 5 August 2010

International Classifications

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

31 January 2008 PCT application entered the National Phase

  PCT publication WO2006/137797 Priority application(s): WO2006/137797

5 August 2010 Application Accepted

  Published as AU-B-2006259898

2 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006259901-Dispenser

2006259897-Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions